ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Shubick Blasts Tobacco Industry Scientists

October 4, 1974

Perot Systems To Provide IT Support For US Oncology Enterprise Applications.

December 15, 2000

NCI, Dept. of Veteran’s Affairs Sign Agreement On Clinical Trials Access

November 1, 1996

Agency Expands Gleevec Label To Include Rare GIST Subset

February 24, 2012

Indoor Tanning Industry Funded Author Of NEJM Review On Vitamin D Deficiency.

April 18, 2008

NCI Director Declines To Fund P-4 Breast Cancer Chemoprevention Trial.

June 22, 2007